Once-Weekly Oral Medicine for Kids’ BRAF Brain Tumors
Ojemda (tovorafenib) — once-weekly oral RAF inhibitor for BRAF-altered pediatric low-grade glioma
FDA accelerated 2024; EC conditional 20 Apr 2026; Swissmedic temporary 5 May 2026; HC NOC/c 13 Jul 2026; FIREFLY-1
This is for children and young people — and caregivers — facing relapsed or refractory pediatric low-grade glioma with a BRAF fusion, rearrangement, or V600…